Rumination Disorder (Rumination Syndrome): Disease-Characteristics Report

Scope and evidence note

This report concerns rumination disorder/rumination syndrome, not depressive or anxiety-related cognitive rumination. The condition crosses classification systems: psychiatry describes rumination disorder as a feeding/eating disorder, whereas gastroenterology commonly describes rumination syndrome as a disorder of gut–brain interaction. The strongest retrieved evidence comprised 2024 expert reviews/consensus statements, primary interventional studies and ClinicalTrials.gov records. Several important 2023–2024 epidemiologic and pediatric articles were indexed but their full text was unavailable to the retrieval system; consequently, unsupported prevalence or outcome estimates are not supplied.

Table: This table summarizes core knowledge-base findings for rumination disorder/syndrome across definition, mechanism, diagnosis, treatment, and evidence gaps. It is designed for rapid curation and explicitly flags domains where no validated genetic, biomarker, infectious, toxic, or animal-model evidence is established.

1. Disease information

Definition and terminology

Rumination disorder is characterized by recurrent, usually effortless regurgitation of recently ingested food during or soon after eating, followed by rechewing, reswallowing, or expulsion. Episodes commonly occur several times per week and often daily. The regurgitation is generated by a learned or subconscious abdominothoracic motor behavior, not by intentional self-induced vomiting, primary structural disease, or ordinary gastroesophageal reflux. A trial protocol states directly: “Rumination disorder (RD; also known as ‘rumination syndrome’) is a disordered eating behavior characterized by the repeated regurgitation of food during or soon after eating.” (NCT03113682 chunk 1)

Synonyms include rumination syndrome, rumination disorder, merycism, and, historically, psychogenic rumination. “Infant rumination syndrome” is a pediatric Rome category, but childhood, adolescent, and adult presentations also occur. The term must not be conflated with repetitive negative thinking in mood disorders.

Identifiers

• MeSH: Rumination Syndrome, D000079562. MeSH places it under gastrointestinal/digestive disease and feeding-and-eating/mental-disorder hierarchies. (NCT03912636 chunk 2)
• DSM-5/DSM-5-TR: Rumination disorder, feeding and eating disorders chapter; commonly coded 307.53 / ICD-10-CM F98.21.
• ICD-10-CM: F98.21, Rumination disorder of infancy; this label is narrower than contemporary all-age usage. In some clinical coding contexts, symptom or functional-GI codes may be used.
• ICD-11: Classified among feeding or eating disorders; the exact browser code should be verified against the jurisdiction-specific current ICD-11 release before ingestion.
• Rome IV: Rumination syndrome is included among functional nausea and vomiting disorders/disorders of gut–brain interaction.
• MONDO: A dedicated current MONDO identifier could not be verified from the retrieved source set; do not assign one without direct MONDO validation.
• OMIM/Orphanet: No established Mendelian disease entry or orphan-disease entity was identified.

The evidence summarized here is aggregated disease-level evidence from consensus papers, reviews, trials, and registries—not individual EHR-derived patient data.

2. Etiology, risk factors, and protective factors

Causal model

No single cause is established. Current understanding favors an acquired, conditioned behavioral–physiologic pattern. Meal-related discomfort, stress, prior gastrointestinal illness or vomiting, and heightened attention to digestive sensations may initiate the behavior in some patients, after which negative reinforcement—temporary relief of pressure or discomfort—may maintain it. These are proposed triggers or perpetuating factors, not necessary causes.

Psychiatric and feeding/eating comorbidities may coexist, but the disorder is not simply intentional behavior or proof of a primary psychiatric cause. GERD and other gastrointestinal disorders can also coexist and may provide an initial regurgitation sensation that becomes conditioned.

Genetic and environmental factors

No causal gene, pathogenic variant, susceptibility locus, inheritance pattern, penetrance estimate, founder effect, carrier frequency, or validated gene–environment interaction has been established. Therefore, ClinVar variant classification, gnomAD allele frequency, germline/somatic origin, and genetic counseling for a rumination-specific mutation are not applicable at present.

No toxin, radiation exposure, pollution source, occupational exposure, infectious organism, smoking pattern, alcohol exposure, or dietary constituent is established as a specific cause. Likewise, no genetic protective allele is known. The best-supported practical protective factors are behavioral: early recognition, correct diagnosis, education, and acquisition of a competing postprandial breathing response.

3. Phenotypes

Core and associated manifestations

• Effortless postprandial regurgitation: the defining symptom; recently ingested, initially recognizable/non-acidic food returns to the mouth. It often starts during or soon after a meal and may recur until gastric contents become acidic. Lyon Consensus 2.0 characterizes rumination as a subconscious learned postprandial behavior and notes that it may cease as the regurgitate becomes acidic. (gyawali2024updatestothe pages 3-3)
• Rechewing, reswallowing, or spitting out: follows regurgitation and is part of the defining behavioral phenotype. (NCT03912636 chunk 1, NCT02214472 chunk 1)
• Absent nausea or retching in typical episodes: helps distinguish rumination from vomiting, although nausea, fullness, or epigastric discomfort can coexist. The vagal-tone study measured nausea, fullness, and epigastric discomfort on 0–5 scales, total 0–15, demonstrating their relevance as associated rather than defining symptoms. (NCT03912636 chunk 2)
• Observable abdominal-wall contraction or “premonitory urge”: may precede regurgitation; patients may initially be unaware of the contraction.
• Nutritional/physical consequences: reduced intake, avoidance of meals, weight loss or poor growth, malnutrition, dehydration, dental erosion, halitosis, and esophageal irritation can occur in severe or prolonged disease. No reliable per-phenotype frequencies were available in the retrieved evidence.
• Behavioral and psychosocial effects: embarrassment, school/work disruption, avoidance of eating socially, anxiety around meals, and caregiver burden can substantially impair quality of life.

Onset, severity, and course

Onset can occur in infancy, childhood, adolescence, or adulthood. Severity ranges from occasional episodes without nutritional compromise to daily, meal-associated regurgitation causing weight loss and hospitalization. The course may be chronic, fluctuating, or relapse after stress or inconsistent practice of competing responses. It is not intrinsically neurodegenerative or progressive.

Suggested HPO mappings

Suggested mappings, requiring validation against the current HPO release, include Regurgitation, Postprandial symptom exacerbation, Feeding difficulties, Weight loss, Failure to thrive, Malnutrition, Nausea, Abdominal discomfort, Dental erosion, and Dehydration. HPO does not fully represent learned behavioral timing and should be supplemented with DSM/Rome annotations and phenotype qualifiers.

4. Genetic and molecular information

No rumination-specific causal gene, HGNC association, pathogenic variant, modifier gene, chromosomal abnormality, epigenetic signature, protein dysfunction, or molecular diagnostic biomarker is established. WES, WGS, gene panels, single-gene testing, CMA, karyotyping, FISH, mitochondrial testing, and repeat-expansion testing have no routine diagnostic role unless another syndromic diagnosis is suspected.

No validated disease-specific transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, multi-omic, CRISPR-screen, or RNAi-screen result was identified. Assertions that particular molecular pathways cause the disorder would currently be speculative.

5. Environmental information

The relevant “environment” is primarily the meal and behavioral context rather than a toxic exposure. Potential precipitating contexts reported clinically include gastrointestinal illness, vomiting, reflux sensations, surgery, psychosocial stress, and meal-associated discomfort. These associations do not establish causality. No infectious agent is implicated, and the condition is neither communicable nor zoonotic.

6. Mechanism and pathophysiology

Causal chain

The best-supported chain is:

1. Meal ingestion or postprandial discomfort provides an internal cue.
2. An initially voluntary or inadvertent behavior becomes a learned, largely subconscious abdominal-wall/abdominothoracic contraction.
3. This raises intragastric pressure while gastroesophageal junction resistance falls or the lower esophageal sphincter relaxes.
4. Gastric contents move retrogradely through the esophagus into the mouth.
5. Rechewing, reswallowing, expulsion, or relief of discomfort reinforces the motor habit.
6. Repeated exposure produces nutritional, mucosal, dental, and psychosocial downstream morbidity.

The primary biofeedback trial describes rumination as “an unperceived, somatic response to food ingestion” and targets abnormal abdominothoracic muscular activity. (NCT02214472 chunk 1) CBT-RD similarly treats the habitual abdominal-wall contraction by habit reversal, using diaphragmatic breathing as a competing response. (NCT03113682 chunk 1, NCT03062696 chunk 1)

Upstream versus downstream mechanisms

Upstream components include meal-related sensation, learned cueing, visceral vigilance, and abdominal-wall activation. The motor event—increased abdominal/intragastric pressure coordinated with reduced sphincter resistance—is proximal to retrograde flow. Regurgitation, mucosal exposure, nutritional compromise, dental injury, and psychosocial avoidance are downstream.

Autonomic regulation is under study rather than established. NCT03912636 compared cardiac vagal tone derived from ECG R–R intervals in patients and healthy volunteers and tested diaphragmatic versus slow deep breathing. Its stated hypothesis was that breathing might improve rumination by altering nervous control of the stomach; this is mechanistic investigation, not proof that vagal dysfunction is causal. (NCT03912636 chunk 1, NCT03912636 chunk 2)

There is no established immune, inflammatory, apoptotic, autophagic, fibrotic, oxidative-stress, enzyme-deficiency, receptor-mutation, ion-channel, or metabolic-pathway mechanism.

Ontology suggestions

Suggested biological-process mappings include skeletal muscle contraction, regulation of digestive-system process, autonomic nervous system process, esophageal motility, and behavioral response to food; current GO identifiers should be checked before ingestion. Suggested Cell Ontology concepts are skeletal muscle cell, smooth muscle cell, enteric neuron, sensory neuron, and autonomic neuron. These are participating cell types, not proven primary cellular lesions.

7. Anatomical structures affected

The functional circuit involves the stomach, gastroesophageal junction/lower esophageal sphincter region, esophagus, diaphragm, intercostal musculature, and abdominal-wall muscles. Secondary injury may affect esophageal and oral/dental tissues. There is no consistent focal histopathologic lesion, lateralization, or disease-specific subcellular compartment.

Suggested UBERON mappings include stomach, esophagus, gastroesophageal junction, diaphragm, abdominal wall, and oral cavity. Relevant tissue classes are skeletal muscle, gastrointestinal smooth muscle, enteric nervous tissue, and esophageal epithelium. Exact UBERON identifiers should be release-validated.

8. Temporal development

Episodes typically begin during or shortly after meals and may repeat for up to one or more postprandial hours. The disorder may begin at any age and can be insidious after an initiating illness or stressor. No universally accepted early/intermediate/advanced staging system exists.

Without recognition, the learned behavior may persist for months or years. Remission can occur with effective behavioral retraining; relapse may occur when practice stops or triggers recur. Early diagnosis is therefore a clinically important intervention window, but a precise “critical period” has not been defined.

9. Inheritance and population

Rumination disorder is not currently considered a Mendelian disease; inheritance, penetrance, anticipation, mosaicism, consanguinity, and carrier status are not applicable. It occurs internationally and in children and adults of all sexes. No robust ethnic or geographic genetic enrichment is established.

Recent global epidemiology and a 2024 systematic review/meta-analysis were identified during searching, but exact pooled prevalence values could not be verified from accessible full text. The defensible conclusion is that prevalence varies materially with case definition, age, clinical versus community ascertainment, and Rome versus DSM criteria. Under-recognition is likely because patients are frequently labeled as having refractory GERD or vomiting. Lyon Consensus 2.0 specifically warns that rumination can masquerade as PPI-refractory GERD. (gyawali2024updatestothe pages 3-3)

Disease-specific incidence per 100,000 person-years, a stable sex ratio, and age-stratified population rates remain insufficiently established in the retrieved evidence.

10. Diagnostics

Clinical criteria

Diagnosis is primarily clinical. The key history is recurrent return of recently ingested food during or soon after meals, usually effortless, without preceding retching, with rechewing/reswallowing/spitting. The clinician should determine meal timing, taste/acidity, abdominal contraction or urge, duration, nutritional effect, intent, and relationship to body-image or compensatory behavior.

Rome IV criteria are commonly used in gastroenterology; DSM criteria additionally require that repeated regurgitation not be attributable to a gastrointestinal/medical condition, occur outside anorexia nervosa, bulimia nervosa, binge-eating disorder, or ARFID—or warrant separate attention if comorbid—and cause clinically significant impairment. The Rome IV vagal-tone study required clinical criteria plus confirmation by high-resolution impedance manometry. (NCT03912636 chunk 2)

Testing

• High-resolution impedance manometry with a postprandial test meal: best objective confirmatory test in uncertain cases. It can show abdominal-pressure increases and retrograde bolus movement and distinguish rumination from supragastric belching or reflux.
• Ambulatory pH-impedance monitoring: useful when GERD remains a concern. Lyon Consensus 2.0 recommends reflux monitoring when behavioral mimics are suspected and emphasizes that treatment differs fundamentally. (gyawali2024updatestothe pages 3-3)
• Endoscopy, imaging, gastric-emptying studies, or routine laboratories: not diagnostic; use selectively for alarm features, nutritional consequences, or plausible alternatives.
• Questionnaires/interviews: PARDI assesses diagnosis, frequency, and severity and served as the principal outcome in CBT-RD pilots. (NCT03113682 chunk 1, NCT03062696 chunk 1)
• Biomarkers/omics/genetics: none validated.

Differential diagnosis

Major alternatives are GERD, gastroparesis, achalasia and other esophageal motility disorders, gastric outlet obstruction, cyclic vomiting syndrome, functional vomiting, supragastric belching, aerophagia, eating disorders involving intentional purging, and structural or neurologic disease. Rumination is tightly meal-linked, usually effortless, and behaviorally generated; vomiting usually involves nausea, autonomic symptoms, and retching. Supragastric belching involves rapid air influx/expulsion rather than gastric food return. Contemporary GERD experts note that rumination and supragastric belching are often misdiagnosed as reflux hypersensitivity and recommend CBT for rumination. (arguero2024pathophysiologyofgastrooesophageal pages 9-10)

There is no population screening, newborn screening, carrier screening, or asymptomatic genetic testing program.

11. Outcome and prognosis

Rumination disorder is generally treatable, especially when recognized and addressed behaviorally. It is not known to reduce life expectancy directly, and disease-specific 5- or 10-year survival statistics are not applicable. Severe untreated disease can nevertheless cause weight loss, poor growth, malnutrition, dehydration, electrolyte disturbance, dental erosion, esophageal irritation, repeated investigations, tube feeding, hospitalization, and substantial educational, occupational, and social disability.

Prognosis is influenced by diagnostic delay, nutritional severity, comorbidity, patient recognition of the premonitory motor response, access to trained behavioral clinicians, and adherence to postprandial practice. No validated molecular prognostic biomarker or mortality model exists. Quantitative long-term remission and relapse rates remain limited and heterogeneous.

12. Treatment

First-line behavioral treatment

Education and diaphragmatic breathing are first-line. The patient is taught slow abdominal breathing before or immediately after meals and at the first urge, creating a motor pattern incompatible with forceful abdominal-wall contraction. Repeated coached practice is preferable to merely providing a handout. Lyon Consensus 2.0 states that rumination requires behavioral therapy rather than acid suppression or antireflux surgery. (gyawali2024updatestothe pages 3-3)

Suggested MAXO mappings, subject to current-release validation, are behavioral therapy, breathing exercise, diaphragmatic breathing, cognitive behavioral therapy, habit-reversal training, biofeedback, nutritional assessment, and enteral nutritional support where medically necessary.

CBT-RD/CBT-RS

Manualized CBT expands breathing training with functional analysis, awareness training, competing responses, exposure to trigger foods/situations, cognitive work, and relapse prevention. The completed MGH pilot enrolled 10 participants aged ≥10 years for 5–8 weekly sessions; PARDI change through three months was the principal outcome. A parallel Drexel record enrolled seven participants. Neither registry record supplied numerical response or adverse-event results, so efficacy percentages should not be inferred. (NCT03113682 chunk 1, NCT03062696 chunk 1)

Biofeedback

EMG-guided biofeedback provides real-time feedback on abdominothoracic activity and teaches control after a challenge meal. The randomized participant-masked trial enrolled 24 adults and delivered three sessions in ten days, measuring regurgitations over 28 days. Registry-linked publications report that muscular control reduced regurgitation; the associated primary reports are PMID 24768808 (published January 2015; DOI: https://doi.org/10.1016/j.cgh.2014.04.018) and PMID 27185077 (published July 2016; DOI: https://doi.org/10.1038/ajg.2016.197). (NCT02214472 chunk 1)

A related 24-person trial evaluated a simplified approach not requiring patient-visible EMG guidance. (NCT02402946 chunk 1)

Pharmacotherapy

No medication corrects an established molecular defect, and drugs are adjunctive rather than first-line.

Baclofen, a GABA-B receptor agonist, can reduce transient lower-esophageal-sphincter relaxations and increase gastroesophageal-junction resistance. A randomized triple-masked crossover Phase 4 study enrolled 20 adults receiving baclofen 10 mg three times daily versus placebo for two weeks; symptoms and postprandial HRIM events were compared. The linked primary publication is PMID 29206813, published January 2018, DOI: https://doi.org/10.1038/ajg.2017.441. (NCT03113396 chunk 1) Sedation, dizziness, weakness, and nausea limit use; withdrawal after prolonged use should be avoided.

A pediatric triple-masked parallel trial, NCT05975684, enrolled 50 children aged 4–18 years. Baclofen 0.5 mg/kg/day up to 15 mg/day in three divided doses was added to usual behavioral care for four weeks; the primary endpoint was the proportion with vomiting no more than weekly. The study is completed, but numerical results were not present in the retrieved registry record. (NCT05975684 chunk 1)

Acid suppression treats coexisting GERD or acid-mediated injury, not the core motor habit. Antiemetics and prokinetics generally do not target the mechanism. Tricyclics or other psychotropics may be used for comorbid disorders but lack a validated rumination-specific pharmacogenomic strategy.

Supportive care and implementation

Assess growth, hydration, electrolytes, dental health, and dietary adequacy. Severe malnutrition may require temporary oral supplements or enteral support while behavioral treatment proceeds. Multidisciplinary pediatric programs may involve gastroenterology, psychology, dietetics, nursing, and occupational/physical therapy. Antireflux surgery is inappropriate for isolated rumination and can worsen diagnostic and therapeutic burden.

Current research

• NCT03912636: completed, 30 participants; compared diaphragmatic, slow deep, and normal breathing and studied cardiac vagal tone. (NCT03912636 chunk 1, NCT03912636 chunk 2)
• NCT05975684: completed pediatric baclofen trial, n=50; results not available in the retrieved record. (NCT05975684 chunk 1)
• NCT06971354: recruiting in 2025, planned n=40, comparing audiovisual/home-practice biofeedback training with placebo and follow-up to six months. This lies beyond the requested 2023–2024 priority window but represents the latest implementation study identified. (NCT06971354 chunk 1)

Gene therapy, cell therapy, RNA therapy, targeted molecular therapy, immunotherapy, and rumination-specific surgery are not applicable.

13. Prevention

No proven primary prevention exists because there is no established infectious, toxic, or genetic cause. Secondary prevention consists of recognizing the characteristic meal-linked pattern early, avoiding repeated low-yield investigations and inappropriate escalation of GERD therapy, and initiating breathing/behavioral treatment promptly. Tertiary prevention includes nutritional surveillance, dental care, management of coexisting GERD or psychiatric illness, and relapse-prevention practice.

There is no vaccine, chemoprophylaxis, genetic carrier screening, prenatal testing, or public-health screening program. Patient and clinician education is the most relevant public-health intervention.

14. Other species and natural disease

Rumination in cattle and other ruminant animals is normal cud-chewing physiology and is not homologous to human rumination disorder. No naturally occurring veterinary disease with validated equivalence, breed association, orthologous causal gene, or zoonotic transmission was identified. Relevant taxonomy examples such as Bos taurus should therefore not be annotated as disease models merely because normal rumination occurs.

15. Model organisms

No validated mouse, rat, zebrafish, invertebrate, cellular, organoid, iPSC, knockout, knock-in, transgenic, or humanized model recapitulates the human learned postprandial syndrome. Human experimental systems—postprandial HRIM/impedance, surface EMG, test meals, respiratory maneuvers, symptom diaries, and biofeedback—are the principal mechanistic models. They reproduce the motor event directly but are limited by small samples, referral bias, learned task performance, and imperfect generalization to everyday meals.

Evidence synthesis and expert assessment

The central expert consensus is that rumination disorder is a recognizable and treatable behavioral motor disorder, not refractory acid reflux. The 2024 Lyon Consensus emphasizes behavioral therapy and avoidance of inappropriate antireflux escalation, while a 2024 Nature Reviews analysis notes frequent confusion with reflux hypersensitivity and supports CBT. (gyawali2024updatestothe pages 3-3, arguero2024pathophysiologyofgastrooesophageal pages 9-10) Primary trials converge on the same mechanism: treatment interrupts abnormal abdominal-wall/abdominothoracic activation through diaphragmatic breathing, habit reversal, or biofeedback; baclofen is a secondary option with much smaller evidence volume. (NCT03113396 chunk 1, NCT02214472 chunk 1)

The principal knowledge gaps are reliable incidence, harmonized DSM-versus-Rome prevalence, age- and sex-stratified natural history, long-term comparative treatment effectiveness, validated patient-reported outcomes, and objective predictors of relapse. Molecular genetics, omics, immunology, and animal models currently do not provide clinically actionable information.

References

1. (gyawali2024updatestothe pages 3-3): C Prakash Gyawali, Rena Yadlapati, Ronnie Fass, David Katzka, John Pandolfino, Edoardo Savarino, Daniel Sifrim, Stuart Spechler, Frank Zerbib, Mark R Fox, Shobna Bhatia, Nicola de Bortoli, Yu Kyung Cho, Daniel Cisternas, Chien-Lin Chen, Charles Cock, Albis Hani, Jose Maria Remes Troche, Yinglian Xiao, Michael F Vaezi, and Sabine Roman. Updates to the modern diagnosis of gerd: lyon consensus 2.0. Gut, 73:361-371, Sep 2024. URL: https://doi.org/10.1136/gutjnl-2023-330616, doi:10.1136/gutjnl-2023-330616. This article has 745 citations and is from a highest quality peer-reviewed journal.

2. (arguero2024pathophysiologyofgastrooesophageal pages 9-10): Julieta Argüero and Daniel Sifrim. Pathophysiology of gastro-oesophageal reflux disease: implications for diagnosis and management. Nature reviews. Gastroenterology & hepatology, 21:282-293, Jan 2024. URL: https://doi.org/10.1038/s41575-023-00883-z, doi:10.1038/s41575-023-00883-z. This article has 78 citations.

3. (NCT03113682 chunk 1): A Study of Cognitive-Behavioral Therapy for Rumination Disorder. Drexel University. 2017. ClinicalTrials.gov Identifier: NCT03113682

4. (NCT03062696 chunk 1): Jennifer Thomas. A Pilot Study of Cognitive-Behavioral Therapy for Rumination Disorder (CBT-RD). Massachusetts General Hospital. 2017. ClinicalTrials.gov Identifier: NCT03062696

5. (NCT03912636 chunk 2): Role of Vagal Tone in Rumination Syndrome. Queen Mary University of London. 2019. ClinicalTrials.gov Identifier: NCT03912636

6. (NCT02214472 chunk 1): Treatment of Rumination by Biofeedback - a Randomized Controlled Trial. Hospital Universitari Vall d'Hebron Research Institute. 2013. ClinicalTrials.gov Identifier: NCT02214472

7. (NCT02402946 chunk 1): Placebo-controlled, Randomized Trial of a Simplified Biofeedback Technique for the Treatment of Rumination. Hospital Universitari Vall d'Hebron Research Institute. 2015. ClinicalTrials.gov Identifier: NCT02402946

8. (NCT03113396 chunk 1): Prof Dr Jan Tack. Baclofen for Rumination. Universitaire Ziekenhuizen KU Leuven. 2012. ClinicalTrials.gov Identifier: NCT03113396

9. (NCT03912636 chunk 1): Role of Vagal Tone in Rumination Syndrome. Queen Mary University of London. 2019. ClinicalTrials.gov Identifier: NCT03912636

10. (NCT05975684 chunk 1): Peter Lu. Baclofen for Children With Rumination Syndrome. Nationwide Children's Hospital. 2023. ClinicalTrials.gov Identifier: NCT05975684

11. (NCT06971354 chunk 1): Treatment of Rumination. Hospital Universitari Vall d'Hebron Research Institute. 2025. ClinicalTrials.gov Identifier: NCT06971354

Artifacts

• Edison artifact artifact-00